Clinical trial
Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma
NCT00057980 · Northwestern University, Other · Completed
Key facts
| NCT number | NCT00057980 |
|---|---|
| Title | Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma |
| Official title | Phase I/II Study of Epirubicin and Celecoxib for Hepatocellular Carcinoma |
| Lead sponsor | Northwestern University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Liver Cancer |
| Intervention type | Drug |
| Interventions | celecoxib, epirubicin hydrochloride |
| Enrollment | 8 |
| Start date | Oct 1, 2002 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2007 |
| First posted | Apr 9, 2003 |
| Last update posted | Jun 11, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: